| Recruiting | 3 | 800 | Europe | Futibatinib, Ivosidenib, Tibsovo, Zanidatamab, Trastuzumab, Zercepac, Neratinib, Nerlynx, Encorafenib, Braftovi, Binimetinib, Mektovi, Niraparib, Zejula, Cisplatin, Gemcitabine | UNICANCER, Cancer Research UK & UCL Cancer Trials Centre, Belgian Group of Digestive Oncology, National Cancer Institute, France, Cancer Research UK, Taiho Oncology, Inc., Servier, Zymeworks BC Inc., Accord Healthcare, Inc., Pierre Fabre Medicament | Biliary Tract Neoplasms | 06/27 | 06/28 | | |
| Active, not recruiting | 2 | 78 | Europe, US | Surufatinib, HMPL-012, sulfatinib | Hutchmed | Neuroendocrine Tumours, Neuroendocrine Tumour of the Lung, Small Intestinal NET | 09/24 | 09/24 | | |
| Recruiting | 2 | 500 | Europe | FOLFOX-A, Gemcitabe and Abraxane, G-CSF | Judith Dixon-Hughes, NHS Greater Glasgow and Clyde, University of Glasgow | Neoplasms Pancreatic | 12/25 | 01/26 | | |
NCT04161417: Precision-Panc Master Protocol: Personalising Treatment for Pancreatic Cancer |
|
|
| Recruiting | N/A | 2500 | Europe | Patients with suspected or confirmed pancreatic cancer will be be asked to provide biopsy material for molecular profiling | Judith Dixon-Hughes, Cancer Research UK, NHS Greater Glasgow and Clyde | Neoplasms Pancreatic | 12/25 | 12/25 | | |
